Literature DB >> 34021126

CD36 promotes NLRP3 inflammasome activation via the mtROS pathway in renal tubular epithelial cells of diabetic kidneys.

Yanjuan Hou1, Qian Wang1, Baosheng Han2, Yiliang Chen3,4, Xi Qiao1, Lihua Wang5.   

Abstract

Tubulointerstitial inflammation plays a key role in the pathogenesis of diabetic nephropathy (DN). Interleukin-1β (IL-1β) is the key proinflammatory cytokine associated with tubulointerstitial inflammation. The NLRP3 inflammasome regulates IL-1β activation and secretion. Reactive oxygen species (ROS) represents the main mediator of NLRP3 inflammasome activation. We previously reported that CD36, a class B scavenger receptor, mediates ROS production in DN. Here, we determined whether CD36 is involved in NLRP3 inflammasome activation and explored the underlying mechanisms. We observed that high glucose induced-NLRP3 inflammasome activation mediate IL-1β secretion, caspase-1 activation, and apoptosis in HK-2 cells. In addition, the levels of CD36, NLRP3, and IL-1β expression (protein and mRNA) were all significantly increased under high glucose conditions. CD36 knockdown resulted in decreased NLRP3 activation and IL-1β secretion. CD36 knockdown or the addition of MitoTempo significantly inhibited ROS production in HK-2 cells. CD36 overexpression enhanced NLRP3 activation, which was reduced by MitoTempo. High glucose levels induced a change in the metabolism of HK-2 cells from fatty acid oxidation (FAO) to glycolysis, which promoted mitochondrial ROS (mtROS) production after 72 h. CD36 knockdown increased the level of AMP-activated protein kinase (AMPK) activity and mitochondrial FAO, which was accompanied by the inhibition of NLRP3 and IL-1β. The in vivo experimental results indicate that an inhibition of CD36 could protect diabetic db/db mice from tubulointerstitial inflammation and tubular epithelial cell apoptosis. CD36 mediates mtROS production and NLRP3 inflammasome activation in db/db mice. CD36 inhibition upregulated the level of FAO-related enzymes and AMPK activity in db/db mice. These results suggest that NLRP3 inflammasome activation is mediated by CD36 in renal tubular epithelial cells in DN, which suppresses mitochondrial FAO and stimulates mtROS production.

Entities:  

Year:  2021        PMID: 34021126     DOI: 10.1038/s41419-021-03813-6

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  41 in total

Review 1.  Mercapturate Pathway in the Tubulocentric Perspective of Diabetic Kidney Disease.

Authors:  Clara Gonçalves-Dias; Judit Morello; M João Correia; Nuno R Coelho; Alexandra M M Antunes; Maria Paula Macedo; Emília C Monteiro; Karina Soto; Sofia A Pereira
Journal:  Nephron       Date:  2019-01-09       Impact factor: 2.847

Review 2.  Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release.

Authors:  Dmitry B Zorov; Magdalena Juhaszova; Steven J Sollott
Journal:  Physiol Rev       Date:  2014-07       Impact factor: 37.312

Review 3.  Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases.

Authors:  Shrikant R Mulay
Journal:  Kidney Int       Date:  2019-03-04       Impact factor: 10.612

4.  NLRP3 deficiency ameliorates renal inflammation and fibrosis in diabetic mice.

Authors:  Ming Wu; Weixia Han; Shan Song; Yunxia Du; Chao Liu; Nan Chen; Haijiang Wu; Yonghong Shi; Huijun Duan
Journal:  Mol Cell Endocrinol       Date:  2018-08-08       Impact factor: 4.102

5.  Thioredoxin-interacting protein links oxidative stress to inflammasome activation.

Authors:  Rongbin Zhou; Aubry Tardivel; Bernard Thorens; Inpyo Choi; Jürg Tschopp
Journal:  Nat Immunol       Date:  2009-12-20       Impact factor: 25.606

Review 6.  Targeting the NLRP3 inflammasome in inflammatory diseases.

Authors:  Matthew S J Mangan; Edward J Olhava; William R Roush; H Martin Seidel; Gary D Glick; Eicke Latz
Journal:  Nat Rev Drug Discov       Date:  2018-07-20       Impact factor: 84.694

Review 7.  Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.

Authors:  Juan F Navarro-González; Carmen Mora-Fernández; Mercedes Muros de Fuentes; Javier García-Pérez
Journal:  Nat Rev Nephrol       Date:  2011-05-03       Impact factor: 28.314

Review 8.  Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy.

Authors:  Yuan-Ye Qiu; Li-Qin Tang
Journal:  Pharmacol Res       Date:  2016-11-05       Impact factor: 7.658

9.  Knockdown of NLRP3 alleviates high glucose or TGFB1-induced EMT in human renal tubular cells

Authors:  Shan Song; Duojun Qiu; Fengwei Luo; Jinying Wei; Ming Wu; Haijiang Wu; Chunyang Du; Yunxia Du; Yunzhuo Ren; Nan Chen; Huijun Duan; Yonghong Shi
Journal:  J Mol Endocrinol       Date:  2018-10-01       Impact factor: 5.098

10.  Stabilization of endogenous Nrf2 by minocycline protects against Nlrp3-inflammasome induced diabetic nephropathy.

Authors:  Khurrum Shahzad; Fabian Bock; Moh'd Mohanad Al-Dabet; Ihsan Gadi; Sumra Nazir; Hongjie Wang; Shrey Kohli; Satish Ranjan; Peter R Mertens; Peter P Nawroth; Berend Isermann
Journal:  Sci Rep       Date:  2016-10-10       Impact factor: 4.379

View more
  14 in total

1.  Activation of the NLRP3 inflammasome by RAC1 mediates a new mechanism in diabetic nephropathy.

Authors:  Changjiang Ying; Zhongyuan Zhou; Jiao Dai; Meng Wang; Jie Xiang; Dong Sun; Xiaoyan Zhou
Journal:  Inflamm Res       Date:  2022-01-14       Impact factor: 4.575

2.  [Oxymatrine improves renal fibrosis and inflammation in diabetic rats by modulating CHK1/2 phosphorylation].

Authors:  Z Li; D Liang; Y Xiao; Y Dai; F Ai; J Ding; M Shi; Y Xiao; B Guo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-10-20

3.  MicroRNA-223 downregulation promotes HBx-induced podocyte pyroptosis by targeting the NLRP3 inflammasome.

Authors:  Yani Yu; Hui Dong; Yue Zhang; Jingyi Sun; Baoshuang Li; Yueqi Chen; Moxuan Feng; Xiaoqian Yang; Shengbo Gao; Wei Jiang
Journal:  Arch Virol       Date:  2022-06-22       Impact factor: 2.685

4.  Bioinformatics prediction and experimental verification of key biomarkers for diabetic kidney disease based on transcriptome sequencing in mice.

Authors:  Jing Zhao; Kaiying He; Hongxuan Du; Guohua Wei; Yuejia Wen; Jiaqi Wang; Xiaochun Zhou; Jianqin Wang
Journal:  PeerJ       Date:  2022-09-20       Impact factor: 3.061

Review 5.  Signaling pathways of chronic kidney diseases, implications for therapeutics.

Authors:  Qian Yuan; Ben Tang; Chun Zhang
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

Review 6.  Epigenetic regulation of Toll-like receptors 2 and 4 in kidney disease.

Authors:  Vishwadeep Shelke; Ajinath Kale; Hans-Joachim Anders; Anil Bhanudas Gaikwad
Journal:  J Mol Med (Berl)       Date:  2022-06-15       Impact factor: 5.606

7.  Identification and Verification of Diagnostic Biomarkers for Glomerular Injury in Diabetic Nephropathy Based on Machine Learning Algorithms.

Authors:  Hongdong Han; Yanrong Chen; Hao Yang; Wei Cheng; Sijing Zhang; Yunting Liu; Qiuhong Liu; Dongfang Liu; Gangyi Yang; Ke Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-19       Impact factor: 6.055

Review 8.  The Role of the NLRP3 Inflammasome in Mediating Glomerular and Tubular Injury in Diabetic Nephropathy.

Authors:  B M Williams; C L Cliff; K Lee; P E Squires; C E Hills
Journal:  Front Physiol       Date:  2022-06-09       Impact factor: 4.755

Review 9.  The role of metabolic reprogramming in tubular epithelial cells during the progression of acute kidney injury.

Authors:  Zhenzhen Li; Shan Lu; Xiaobing Li
Journal:  Cell Mol Life Sci       Date:  2021-06-29       Impact factor: 9.261

10.  Qihu Preparation Ameliorates Diabetes by Activating the AMPK Signaling Pathway in db/db Mice.

Authors:  Hongfang Zeng; Xiaoli Li; Duanfang Zhou; Ning Wang; Xiaoping Yu; Liangyuan Long; Hao Cheng; Shuyu Zhou; Zhengze Shen; Weiying Zhou
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-14       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.